The clinical characteristics, survival and prognosis of 27 mantle cell lymphoma patients.

Objective To analyze the clinical characteristics,therapeutic outcome and prognostic factors of mantle cell lymphoma(MCL)in China.Methods Clinical records of 27 MCL patients were retrospectively analyzed.The results of rituximab combined therapy and conventional therapy regimens were compared,and prognostic factors were analyzed.Results The median age of the 27 patients was 59,with marked male predominance(2.4∶1).There were 88.9% patients with bone marrow involvement at clinical stage Ⅲ～Ⅳ,59.3% with spleen involvement,44.4% with LDH elevated,33.3% with B symptoms and 11.1% with liver involvement.Among the 21 patient with conventional cytogenetic results,7 patients had additional chromosome aberration and 4 patients had more than 4 chromosomes aberration.15/20 patients were misdiagnosed in local hospitals,most of which were diagnosed as CLL/SLL.In 24 untreated patients,the CR/CRu,3 years' OS and PFS in rituximab combined therapy(RCT group)were all significantly higher than those in CT group(87.5% vs 31.3%,87.5% vs 24.1%,70.0% vs 26.9%,P0.05 respectively).Age older than 60,B symptoms,liver involvement,elevated LDH,hemoglobin less than 110 g/L,albumin less than 40 g/L and more than 3 chromosomes aberration were negative prognostic factors,but bone marrow involvement,spleen involvement and clinical stage didn't affect prognosis.4 patients with more than 4 chromosomes aberration had the worse outcome with median survival of only 3.5 months.Conclusion The clinical characteristics of MCL in China are comparable with those in other countries,but with high misdiagnosis,which is worth more investigation.The rituximab combined therapy regimen should be the first line therapy option for MCL.